Clinical Outcomes of Atezolizumab Versus Standard-of-care Docetaxel with and Without Ramucirumab in Patients with Advanced Non-small-cell Lung Cancer Who Received Prior Immunotherapy

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Feb 22

PMID 38384808

Authors

Shenduo Li

Rami Manochakian

Ruqin Chen

Jaydeepbhai Patel

Jyothik Varun Inampudi

Koshiya R Hiren

Yujie Zhao

Yanyan Lou

Affiliations

Soon will be listed here.

Abstract

Background: Atezolizumab is superior to docetaxel for patients with advanced non-small-cell lung cancer (NSCLC) who are pretreated with platinum-based chemotherapy based on the POPLAR and OAK trials. However, patients who received prior immunotherapy were excluded from these trials. The standard of care second-line therapy for these patients remains to be docetaxel with or without ramucirumab. The efficacy and safety of atezolizumab as a subsequent therapy in immunotherapy-pretreated patients are unknown.

Methods: We conducted a retrospective study of all patients with locally advanced or metastatic NSCLC who were pretreated with immunotherapy at Mayo Clinic Jacksonville and Rochester from 2016 to 2022. Patients who received subsequent therapy of atezolizumab alone (Atezo), docetaxel (Doce), or docetaxel + ramucirumab (Doce+Ram) were included.

Results: In this cohort of 165 patients, 12.7% (n=21), 49.1% (n=81), and 38.2% (n=63) patients received subsequent Atezo, Doce, and Doce+Ram, respectively. 1-year landmark progression-free survival (PFS) were 23.8%, 6.2%, and 3.2% (p=0.006), and 2-year landmark PFS were 14.3%, 0%, and 0% (p<0.0001), in the Atezo, Doce, and Doce+Ram groups, respectively. About 20% patients with positive PD-L1 had durable response to atezolizumab. The Atezo group showed significantly greater overall survival (OS) improvement over Doce group (median OS 17.7 vs. 7.7 months, HR 0.47, 95% CI 0.29 - 0.76, p=0.008), and over Doce+Ram group (median OS 17.7 vs. 8.9 months, HR 0.55, 95% CI 0.32 - 0.95, p=0.047). 4 of 21 (19%) patients in the Atezo group developed immune-related adverse events (irAE).

Conclusion: We observed statistically significant and clinically meaningful overall survival benefits of atezolizumab monotherapy compared with docetaxel +/- ramucirumab in patients with advanced NSCLC who were pretreated with immunotherapy. The survival benefit seems to be mainly from PD-L1 positive patients. Subsequent immunotherapy with Atezolizumab did not increase irAE rate.

References

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Nakamura A, Yamaguchi O, Mori K, Miura K, Tamiya M, Oba T . Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). Eur J Cancer. 2023; 184:62-72. DOI: 10.1016/j.ejca.2023.01.025. View

Ishida M, Morimoto K, Yamada T, Shiotsu S, Chihara Y, Yamada T . Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study. Thorac Cancer. 2021; 13(2):173-181. PMC: 8758423. DOI: 10.1111/1759-7714.14236. View

Reckamp K, Redman M, Dragnev K, Minichiello K, Villaruz L, Faller B . Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A. J Clin Oncol. 2022; 40(21):2295-2306. PMC: 9287284. DOI: 10.1200/JCO.22.00912. View

Nosaki K, Saka H, Hosomi Y, Baas P, de Castro Jr G, Reck M . Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer. 2019; 135:188-195. DOI: 10.1016/j.lungcan.2019.07.004. View

Zhang Y, Song Q, Cassady K, Lee M, Tang H, Zheng M . Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity. Proc Natl Acad Sci U S A. 2023; 120(16):e2205085120. PMC: 10120074. DOI: 10.1073/pnas.2205085120. View

Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Bharat A . Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(5):497-530. DOI: 10.6004/jnccn.2022.0025. View

Fujita K, Uchida N, Kanai O, Okamura M, Nakatani K, Mio T . Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases. Cancer Chemother Pharmacol. 2018; 81(6):1105-1109. DOI: 10.1007/s00280-018-3585-9. View

Mazieres J, Rittmeyer A, Gadgeel S, Hida T, Gandara D, Cortinovis D . Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials. J Thorac Oncol. 2020; 16(1):140-150. DOI: 10.1016/j.jtho.2020.09.022. View

10.

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. J Clin Oncol. 2021; 39(21):2339-2349. PMC: 8280089. DOI: 10.1200/JCO.21.00174. View

11.

Mushti S, Mulkey F, Sridhara R . Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials. Clin Cancer Res. 2018; 24(10):2268-2275. DOI: 10.1158/1078-0432.CCR-17-1902. View

12.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

13.

Kitagawa S, Hakozaki T, Kitadai R, Hosomi Y . Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review. Thorac Cancer. 2020; 11(7):1927-1933. PMC: 7327670. DOI: 10.1111/1759-7714.13483. View

14.

Mok T, Lopes G, Cho B, Kowalski D, Kasahara K, Wu Y . Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Ann Oncol. 2023; 34(4):377-388. DOI: 10.1016/j.annonc.2023.01.011. View

15.

Shukuya T, Mori K, Amann J, Bertino E, Otterson G, Shields P . Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies. J Thorac Oncol. 2016; 11(11):1927-1939. PMC: 7086375. DOI: 10.1016/j.jtho.2016.07.017. View

16.

Zhao P, Li L, Jiang X, Li Q . Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019; 12(1):54. PMC: 6544911. DOI: 10.1186/s13045-019-0738-1. View

17.

Zhao Y, Lee C, Lin C, Gassen R, Xu X, Huang Z . PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. Immunity. 2019; 51(6):1059-1073.e9. PMC: 6935268. DOI: 10.1016/j.immuni.2019.11.003. View

18.

Herbst R, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios C . Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020; 383(14):1328-1339. DOI: 10.1056/NEJMoa1917346. View

19.

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016; 389(10066):255-265. PMC: 6886121. DOI: 10.1016/S0140-6736(16)32517-X. View

20.

Berghmans T, Pasleau F, Paesmans M, Bonduelle Y, Cadranel J, Cs Toth I . Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations. Eur Respir J. 2011; 39(1):9-28. DOI: 10.1183/09031936.00190310. View